pipette
ENEnglish

Dual CD40/CD28 co-stimulation reprograms the solid-tumor microenvironment to unleash CAR-T and endogenous anti-tumor immunity

Z. Zi, J. Feng, C. Han, F. Yang, J. Wang, G. Zhu, X. Liu, Y. Zhao

PreprintUso en el mundo real

En palabras de los autores

Chimeric antigen receptor (CAR) T-cell therapy has shown limited efficacy against solid tumors, owing to poor T-cell persistence, an immunosuppressive tumor microenvironment (TME) and cancer immune evasion. Here we describe LACO-Stim (lymphocytes-APC co-stimulator), a chimeric co-stimulatory molecule composed of an agonistic anti-CD40 single-chain variable fragment (scFv) and the CD28 intracellular signaling domain, such that a single molecule activates CD40-expressing antigen-presenting cells while delivering CD28 co-stimulation to the T cell that bears it. Co-expressed with a 4-1BB-based CAR (LACO-CAR-T), it enhanced anti-tumor activity in vitro and achieved durable, complete in most mice, tumor regression rather than transient control in xenograft and immunocompetent models. In immunocompetent hosts, LACO-CAR-T activated dendritic cells, reprogrammed tumor macrophages toward M1-like, antigen-presenting states, and induced epitope spreading with endogenous CD8 T-cell responses against tumor neoantigens. Single-cell transcriptomics and RNA-velocity analysis revealed coordinated immune remodeling: T cells shifted toward a more stem-like, less terminally exhausted state, regulatory T cells declined in frequency and suppressive function, and myeloid cells acquired antigen-presentation programs while excessive inflammatory and suppressive signaling was restrained. LACO-Stim further synergized with anti-PD-1 blockade to control tumor growth. LACO-Stim thus enables CAR-T cells to coordinate intrinsic T-cell reinforcement with extrinsic immune reprogramming, converting an immunosuppressive TME into a de-inflamed (reduced inflammatory signaling), de-suppressed rather than merely armed niche that supports endogenous anti-tumor immunity.

Resultado principalEl resumen no menciona limitaciones.

Apareció: miércoles, 11 de noviembre. bioRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.11.08.762395